Detailed description of drug properties and clinical application of Fidaxomicin tablets

Fidaxomicin is a new macrolide antibiotic with highly selective activity against anaerobic bacteria, especially against Clostridioides difficile (Clostridioides difficile, C. difficile) infection. Its drug properties show that it is rarely absorbed in the gastrointestinal tract after oral administration, and its main effect is limited to the intestinal lumen. Therefore, systemic exposure is extremely low and the risk of systemic toxicity is reduced. This feature makes it a first-line drug of choice for the treatment of C. difficile-associated diarrhea (CDAD), while having little impact on the normal intestinal flora.

In terms of clinical application, fidaxomicin is mainly used to treat C. difficile infections in adults and children, especially for patients with recurrent CDAD. Multiple clinical studies have shown that compared with vancomycin, fidaxomicin has a similar initial cure rate but a significantly lower recurrence rate. This is due to its unique antibacterial mechanism and high local concentration in the intestine. Its standard usage is 200mg taken orally, once every 12 hours. The course of treatment is usually 10 days. Patients can adjust the dosage according to the doctor's advice.

The pharmacological mechanism of fidaxomicin is to inhibit the activity of bacterial RNA polymerase and prevent RNA synthesis, thereby effectively blocking the proliferation of C. difficile. Compared with other broad-spectrum antibiotics, it is more targeted, has less interference with intestinal symbiotic flora, and helps maintain the balance of intestinal microecology. This mechanism can not only clear the source of infection, but also reduce the risk of reinfection caused by bacterial imbalance, providing an effective intervention for C. difficile infection with high recurrence rate.

During use, patients should pay attention to drug tolerance and possible adverse reactions. Common adverse reactions of fidaxomicin include nausea, vomiting, abdominal pain and mild diarrhea, most of which are transient and resolve spontaneously. Due to its limited oral absorption, patients with abnormal liver and kidney function generally do not need to adjust the dosage, but should be used under the guidance of a doctor. In addition, in order to ensure the curative effect, patients should complete the full course of treatment as prescribed and not stop medication or skip doses at will to reduce the risk of infection recurrence. Taken together, fidaxomicin, with its high selectivity, low systemic toxicity and significantly reduced recurrence rate, has obvious advantages in the treatment of C. difficile infection and is one of the first-choice local intestinal antibiotics in clinical practice.

Reference link:https://www.drugs.com